Which of the following is not a pharmacological propey of Repaglinide?

Repaglinide: the first member of the group, was approved for clinical use in 1998. These drugs modulate B cell insulin release by regula ng potassium efflux through the potassium channels. It should be taken just before each meal in doses of 0.25-4 mg; hypoglycemia is a risk if the meal is delayed or skipped or contains inadequate carbohydrate.